Compare WSO & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSO | VTRS |
|---|---|---|
| Founded | 1945 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 14.8B |
| IPO Year | N/A | N/A |
| Metric | WSO | VTRS |
|---|---|---|
| Price | $385.71 | $13.09 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 8 | 6 |
| Target Price | ★ $413.33 | $11.50 |
| AVG Volume (30 Days) | 369.8K | ★ 9.3M |
| Earning Date | 02-17-2026 | 02-26-2026 |
| Dividend Yield | 3.19% | ★ 3.79% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 12.87 | N/A |
| Revenue | $7,414,495,000.00 | ★ $14,124,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | $1.18 |
| P/E Ratio | $29.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $323.05 | $6.85 |
| 52 Week High | $535.40 | $13.49 |
| Indicator | WSO | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 68.76 | 65.25 |
| Support Level | $369.85 | $12.55 |
| Resistance Level | $382.37 | $13.49 |
| Average True Range (ATR) | 11.42 | 0.34 |
| MACD | 3.01 | -0.02 |
| Stochastic Oscillator | 95.39 | 68.08 |
Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue), with significant exposure in the Sun Belt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.